MD Anderson, Exscientia collaborate on AI-powered drug development

Houston-based University of Texas MD Anderson Cancer Center is collaborating with artificial intelligence company Exscientia to develop new oncology treatments.

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive